GlassScriptPhysician profile
Jan H Burger
NPI 1215001979
$15,551.72
in general payments reported to CMS, 2019-2025
68 companies · $2,305 in 2025
The $2,305 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,858 · 2020: $1,788 · 2021: $2,288 · 2022: $1,933 · 2023: $2,649 · 2024: $2,732 · 2025: $2,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,685.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,529.08 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,482.55 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $1,459.52 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $1,330.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,080.01 | 2019-2025 | |
| Glaxosmithkline, LLC. | $801.16 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $791.62 | 2019-2025 | Otezla, Repatha, Repatha |
| Supernus Pharmaceuticals, INC. | $693.73 | 2019-2024 | Qelbree, Qelbree, Tlando |
| Bayer Healthcare Pharmaceuticals INC. | $457.16 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $436.56 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amarin Pharma, INC. | $417.87 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $363.19 | 2019-2025 | Spravato, Xarelto |
| Exact Sciences Corporation | $358.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $312.33 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $250.24 | 2019-2023 |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Burger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.